GlassScriptPhysician profile
Cindy S Marrow
NPI 1407842263
$10,842.53
in general payments reported to CMS, 2019-2025
57 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 91% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $1,403 · 2021: $1,487 · 2022: $1,386 · 2023: $1,841 · 2024: $1,476 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,940 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,940.43 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,216.70 | 2020-2025 | |
| Novo Nordisk INC | $1,029.07 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $801.16 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $764.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $703.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $656.98 | 2019-2025 | Rexulti |
| Amgen INC. | $569.36 | 2019-2025 | Evenity, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $467.57 | 2019-2024 | Xifaxan |
| Allergan, INC. | $441.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $392.17 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $344.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $307.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $291.19 | 2022-2025 | Rexulti, Vyepti |
| Astellas Pharma US INC | $241.81 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.18 | 2019-2025 | Jardiance |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Marrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.